Intercellular adhesion molecule 1 (ICAM1) is a transmembrane glycoprotein constitutively expressed at low levels in endothelial cells, pericytes, and on some monocytes and lymphocytes. Creative Biolabs provides a diverse range of assays to assess ICAM1 protein. We can also run custom assays to meet your specific needs. Our breadth of technical platforms provides for singleplex or multiplex data options. Whether you decide on an off-the-shelf solution or a highly customized assay for ICAM1 analysis, we have the immunology solution you need to further your drug development program.
ICAM1, also known as CD54, is a transmembrane cell surface glycoprotein that interacts with two integrins important for the trans-endothelial migration of leukocytes. ICAM1 consists of five distinct Ig-like domains, a transmembrane domain, and a short cytoplasmic tail. It has a molecular weight of 85 to 110 kDa depending on the level of glycosylation. ICAM1 mainly binds to lymphocyte function-associated antigen 1 (LFA-1) and macrophage antigen 1 (Mac-l) as receptors that are essential for cell-cell and cell-matrix adhesive interactions and activation of signal-transduction into the cellular pathways. Moreover, ICAM1-fibrinogen interactions have been shown to enhance leukocyte adhesion and neutrophil transmigration.
Fig.1 Overview of ICAM1. (Bui, et al., 2020)
The level of ICAM1 expression is upregulated in response to some inflammatory stimulations such as pathogen infection and proinflammatory cytokines. The soluble form of ICAM1 (sICAM1) is derived from the membrane form of ICAM1 (mICAM1) by proteolysis, and sICAM1 has been revealed as a candidate marker for vascular inflammation. sICAM1 fulfills enough suitable criteria to regard it as a marker of vascular inflammation.
Creative Biolabs provides professional and comprehensive analysis services for ICAM1 identification and quantification. In addition, with the assistance of powerful bioinformatics techniques, we can also help you with data interpretation & deeper mining to screen out potential biomarkers. With years of unremitting efforts, Creative Biolabs has developed an innovative new assay that combines the specificity and ease of use of an ELISA with the sensitivity of real-time PCR (RT-PCR) to enrich our detection platform. This results in an assay that is simultaneously familiar and cutting edge and enables the use of lower sample volumes while also providing more sensitivity.
Creative Biolabs has the depth and breadth of expertise, tools, and capabilities to prepare and implement strategies to help drug developers effectively gain a competitive advantage - helping ensure your success in new product launches. Creative Biolabs is your partner of choice for any program which requires biomarker identification, assay development, qualification, and analysis to meet customer requirements.
If you are interested in our analysis services, please feel free to contact us for more information.
Reference
For Research Use Only.
